GlassScriptPhysician profile
Vytautas Pukis
NPI 1225270440
$16,216.60
in general payments reported to CMS, 2019-2025
60 companies · $1,664 in 2025
The $1,664 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,687 · 2020: $2,732 · 2021: $2,826 · 2022: $2,498 · 2023: $2,762 · 2024: $2,048 · 2025: $1,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,473.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,143.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,545.97 | 2020-2025 | |
| Ucb, INC. | $1,002.29 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $984.34 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $786.66 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Antares Pharma, INC. | $752.92 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $594.88 | 2019-2024 | Jardiance, Synjardy, Trijardy Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $580.01 | 2019-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $562.62 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Pfizer INC. | $537.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $517.42 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $424.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $400.56 | 2020-2024 | Freestyle Libre 3, Proclaim |
| Tolmar, INC. | $328.43 | 2023-2025 | Jatenzo |
| Amgen INC. | $311.03 | 2019-2025 | Prolia, Evenity, Repatha |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vytautas Pukis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.